JP6479029B2 - ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 - Google Patents

ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 Download PDF

Info

Publication number
JP6479029B2
JP6479029B2 JP2016550483A JP2016550483A JP6479029B2 JP 6479029 B2 JP6479029 B2 JP 6479029B2 JP 2016550483 A JP2016550483 A JP 2016550483A JP 2016550483 A JP2016550483 A JP 2016550483A JP 6479029 B2 JP6479029 B2 JP 6479029B2
Authority
JP
Japan
Prior art keywords
mmol
carboxylate
compound according
tert
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016550483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505323A (ja
Inventor
ブラウン，ジャイルズ・アルバート
キャンズフィールド，ジュリー・エレイン
コングリーヴ，マイルズ・スチュアート
オブライエン，マイケル・アリスター
ピックワース，マーク
ラッカム，マーク・デーヴィッド
テハン，ベンジャミン・ジェラルド
テオボールド，バリー・ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52465550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6479029(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1402013.5A external-priority patent/GB201402013D0/en
Priority claimed from GBGB1416622.7A external-priority patent/GB201416622D0/en
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of JP2017505323A publication Critical patent/JP2017505323A/ja
Application granted granted Critical
Publication of JP6479029B2 publication Critical patent/JP6479029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
JP2016550483A 2014-02-06 2015-02-06 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 Active JP6479029B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1402013.5A GB201402013D0 (en) 2014-02-06 2014-02-06 Pharmaceutical compounds
GB1402013.5 2014-02-06
GB1416622.7 2014-09-19
GBGB1416622.7A GB201416622D0 (en) 2014-09-19 2014-09-19 Pharmaceutical compounds
PCT/GB2015/050331 WO2015118342A1 (en) 2014-02-06 2015-02-06 Bicyclic aza compounds as muscarinic m1 receptor agonists.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019017086A Division JP6774513B2 (ja) 2014-02-06 2019-02-01 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Publications (2)

Publication Number Publication Date
JP2017505323A JP2017505323A (ja) 2017-02-16
JP6479029B2 true JP6479029B2 (ja) 2019-03-06

Family

ID=52465550

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2016550483A Active JP6479029B2 (ja) 2014-02-06 2015-02-06 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2019017086A Active JP6774513B2 (ja) 2014-02-06 2019-02-01 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2020168341A Withdrawn JP2021006571A (ja) 2014-02-06 2020-10-05 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023060030A Active JP7652829B2 (ja) 2014-02-06 2023-04-03 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076025A Active JP7652833B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076024A Active JP7652832B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2025041135A Pending JP2025085736A (ja) 2014-02-06 2025-03-14 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2019017086A Active JP6774513B2 (ja) 2014-02-06 2019-02-01 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2020168341A Withdrawn JP2021006571A (ja) 2014-02-06 2020-10-05 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023060030A Active JP7652829B2 (ja) 2014-02-06 2023-04-03 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076025A Active JP7652833B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2023076024A Active JP7652832B2 (ja) 2014-02-06 2023-05-02 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2025041135A Pending JP2025085736A (ja) 2014-02-06 2025-03-14 ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Country Status (30)

Country Link
US (6) US9670183B2 (https=)
EP (4) EP4714446A2 (https=)
JP (7) JP6479029B2 (https=)
KR (1) KR102352388B1 (https=)
CN (2) CN109851610B (https=)
AU (3) AU2015213900B2 (https=)
BR (1) BR112016017979B1 (https=)
CA (1) CA2938169C (https=)
CL (1) CL2016001983A1 (https=)
CY (1) CY1120834T1 (https=)
DK (2) DK3102568T3 (https=)
ES (2) ES2688548T3 (https=)
FI (1) FI3406609T3 (https=)
HR (2) HRP20181499T1 (https=)
HU (1) HUE068301T2 (https=)
IL (1) IL247117B (https=)
LT (2) LT3406609T (https=)
MX (2) MX371529B (https=)
NZ (1) NZ723103A (https=)
PH (1) PH12016501570B1 (https=)
PL (2) PL3102568T3 (https=)
PT (2) PT3102568T (https=)
RS (2) RS65894B1 (https=)
RU (1) RU2685230C2 (https=)
SA (1) SA516371614B1 (https=)
SG (1) SG11201606269WA (https=)
SI (2) SI3102568T1 (https=)
SM (1) SMT202400446T1 (https=)
UA (1) UA122121C2 (https=)
WO (1) WO2015118342A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077725A (ja) * 2014-02-06 2019-05-23 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
GB201404922D0 (en) * 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2018002760A1 (en) * 2016-07-01 2018-01-04 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
JP7134173B2 (ja) 2017-06-21 2022-09-09 第一三共株式会社 Ｅｐ３００／ｃｒｅｂｂｐ阻害剤
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
US12600726B2 (en) 2017-07-12 2026-04-14 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP7166331B2 (ja) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
IL310346A (en) 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
EP3732163A4 (en) * 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP4219464A1 (en) 2018-03-23 2023-08-02 Pfizer Inc. Piperazine azaspiro derivaves
GB201810245D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
PE20221454A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
KR20220079921A (ko) * 2019-10-09 2022-06-14 노파르티스 아게 M4 작용제로서의 2-아자스피로[3.4]옥탄 유도체
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
EP4100410B1 (en) * 2020-02-05 2026-04-22 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
US11912705B2 (en) * 2020-08-20 2024-02-27 The Corporation Of Mercer University Cathinone derivatives, pharmaceutical formulations, and methods
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
DK4508045T3 (da) 2022-08-04 2025-10-20 Nxera Pharma Uk Ltd Citratsalt-former af en muskarinreceptor-agonist
KR20250086639A (ko) * 2022-09-16 2025-06-13 세레벨 쎄라퓨틱스, 엘엘씨 M4 활성제/조절제 및 이의 용도
EP4649077A1 (en) * 2023-01-12 2025-11-19 Cerevel Therapeutics, LLC Spiro derivatives as m4 activators/modulators and uses thereof
JP2026503599A (ja) * 2023-01-24 2026-01-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 重水素化化合物
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法
WO2025030095A1 (en) 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis
WO2026050238A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist for use in the treatment of a neurological or psychiatric disorder
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
WO2026050229A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a neurological or psychiatric disease or disorder
WO2026050231A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a bipolar disorder
WO2026050225A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a neurological or psychiatric disease or disorder
WO2026050278A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Solid oral pharmaceutical formulations comprising a muscarinic receptor agonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
AU2206699A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JPWO2002085890A1 (ja) * 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
CN101426499A (zh) 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
NZ570497A (en) * 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
BRPI0708524A2 (pt) * 2006-03-03 2011-05-31 Novartis Ag compostos de n-formil hidroxilamina
GB0706188D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
JP2012506883A (ja) 2008-10-29 2012-03-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスピロアミン
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2012020813A1 (ja) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 縮環ピロリジン誘導体
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
BR112015006029B1 (pt) * 2012-09-18 2022-01-25 Heptares Therapeutics Limited Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias
EP2991980B1 (en) 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015118057A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
KR102352388B1 (ko) 2014-02-06 2022-01-17 헵테얼즈 테라퓨틱스 리미티드 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물
JP6581100B2 (ja) 2014-02-06 2019-09-25 リボサイエンス・エルエルシー インフルエンザｒｎａ複製の阻害剤としての４’−ジフルオロメチル置換ヌクレオシド誘導体
MA39484A (fr) 2014-09-19 2016-03-24 Bayer Pharma AG Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1
WO2016044789A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
EA033697B1 (ru) 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077725A (ja) * 2014-02-06 2019-05-23 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP2021006571A (ja) * 2014-02-06 2021-01-21 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP7652832B2 (ja) 2014-02-06 2025-03-27 ネクセラ・ファーマ・ユーケイ・リミテッド ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP7652829B2 (ja) 2014-02-06 2025-03-27 ネクセラ・ファーマ・ユーケイ・リミテッド ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
JP7652833B2 (ja) 2014-02-06 2025-03-27 ネクセラ・ファーマ・ユーケイ・リミテッド ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物

Also Published As

Publication number Publication date
CA2938169A1 (en) 2015-08-13
JP2023073504A (ja) 2023-05-25
US20170015650A1 (en) 2017-01-19
HRP20241145T1 (hr) 2024-11-22
MX2016010322A (es) 2017-04-27
US9670183B2 (en) 2017-06-06
PH12016501570A1 (en) 2016-10-03
BR112016017979B1 (pt) 2022-08-02
RU2016133684A (ru) 2018-03-14
JP2021006571A (ja) 2021-01-21
AU2020277225A1 (en) 2020-12-24
US20190112294A1 (en) 2019-04-18
EP4714446A2 (en) 2026-03-25
SI3102568T1 (sl) 2018-11-30
AU2019201579B2 (en) 2020-08-27
MX371529B (es) 2020-01-31
JP2025085736A (ja) 2025-06-05
AU2019201579A1 (en) 2019-03-28
DK3406609T3 (da) 2024-08-26
WO2015118342A8 (en) 2016-06-30
US9926297B2 (en) 2018-03-27
US10961225B2 (en) 2021-03-30
FI3406609T3 (fi) 2024-09-10
CA2938169C (en) 2022-03-15
HUE068301T2 (hu) 2024-12-28
CN109851610A (zh) 2019-06-07
JP2017505323A (ja) 2017-02-16
US10385039B2 (en) 2019-08-20
RS65894B1 (sr) 2024-09-30
DK3102568T3 (en) 2018-10-08
PL3102568T3 (pl) 2019-01-31
PT3406609T (pt) 2024-09-17
AU2015213900A1 (en) 2016-08-11
SA516371614B1 (ar) 2019-10-30
US10689368B2 (en) 2020-06-23
KR102352388B1 (ko) 2022-01-17
RU2016133684A3 (https=) 2018-08-31
AU2015213900B2 (en) 2018-12-13
JP2019077725A (ja) 2019-05-23
JP6774513B2 (ja) 2020-10-28
JP7652832B2 (ja) 2025-03-27
EP3406609A1 (en) 2018-11-28
HRP20181499T1 (hr) 2018-11-30
EP3406609B1 (en) 2024-06-26
CL2016001983A1 (es) 2017-06-23
US20180179184A1 (en) 2018-06-28
JP7652829B2 (ja) 2025-03-27
NZ723103A (en) 2022-09-30
IL247117A0 (en) 2016-09-29
SMT202400446T1 (it) 2024-11-15
CN106458986A (zh) 2017-02-22
MX2020001236A (es) 2022-06-30
JP7652833B2 (ja) 2025-03-27
EP3102568A1 (en) 2016-12-14
RU2685230C2 (ru) 2019-04-17
ES2688548T3 (es) 2018-11-05
SI3406609T1 (sl) 2024-10-30
JP2023087046A (ja) 2023-06-22
CN109851610B (zh) 2021-09-21
EP4413985A2 (en) 2024-08-14
UA122121C2 (uk) 2020-09-25
US20200325118A1 (en) 2020-10-15
PH12016501570B1 (en) 2016-10-03
HK1231473A1 (en) 2017-12-22
ES2986327T3 (es) 2024-11-11
US20190337925A1 (en) 2019-11-07
LT3102568T (lt) 2018-11-12
WO2015118342A1 (en) 2015-08-13
KR20160129014A (ko) 2016-11-08
US20170240530A1 (en) 2017-08-24
EP3102568B1 (en) 2018-06-27
CN106458986B (zh) 2019-01-04
MX393637B (es) 2025-03-11
CY1120834T1 (el) 2019-12-11
JP2023087045A (ja) 2023-06-22
US10196380B2 (en) 2019-02-05
LT3406609T (lt) 2024-09-25
PT3102568T (pt) 2018-10-24
IL247117B (en) 2021-03-25
PL3406609T3 (pl) 2024-11-25
BR112016017979A2 (https=) 2017-08-08
SG11201606269WA (en) 2016-09-29
RS57843B1 (sr) 2018-12-31
EP4413985A3 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
JP7652833B2 (ja) ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
RU2811601C1 (ru) Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
RU2811601C9 (ru) Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
HK40114593A (en) Pharmaceutical compounds
HK40007500A (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
HK40007500B (zh) 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物
HK1231473B (en) Bicyclic aza compounds as muscarinic m1 receptor agonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190205

R150 Certificate of patent or registration of utility model

Ref document number: 6479029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250